0001209191-20-028394.txt : 20200511
0001209191-20-028394.hdr.sgml : 20200511
20200511201718
ACCESSION NUMBER: 0001209191-20-028394
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200507
FILED AS OF DATE: 20200511
DATE AS OF CHANGE: 20200511
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ABERNETHY MATT
CENTRAL INDEX KEY: 0001724097
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 20866744
MAIL ADDRESS:
STREET 1: C/O NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-07
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001724097
ABERNETHY MATT
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Financial Officer
Common Stock
2020-05-07
4
M
0
15000
73.60
A
20953
D
Common Stock
2020-05-07
4
S
0
15000
110.2089
D
5953
D
Non-Qualified Stock Option
73.60
2020-05-07
4
M
0
15000
73.60
D
2027-12-01
Common Stock
15000
45000
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Option granted December 1, 2017 and vested at 25% upon first anniversary (December 1, 2018) and remaining 75% vesting in 36 equal monthly installments beginning November 1, 2018.
/s/ Darin Lippoldt, Attorney-in-Fact
2020-05-11